Clinical Trials

Gan And Lee Pharmaceuticals Reports Phase 3 Success For Once Weekly Insulin GZR4

Gan & Lee Pharmaceuticals announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating investigative once-weekly insulin GZR4 In...

 April 02, 2026 | News

Abbisko Therapeutics Secures EMA Orphan Drug Status For Irpagratinib In Liver Cancer

Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that its independently developed, highly selective, oral...

 April 02, 2026 | News

Delonix Bioworks Initiates First In Human Trial Of DX 104 For Meningococcal B Vaccine

Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, today announced the initiation of first-in-h...

 April 01, 2026 | News

Hengrui Pharma And Braveheart Bio Report Strong Phase 2 Results For HRS 1893 In Obstructive Hypertrophic Cardiomyopathy

Results of dose-ranging study suggest potential for best-in-class clinical profile across efficacy, safety and ease of use, including s...

 April 01, 2026 | News

Centivax Secures 37 Million Dollars In Oversubscribed Financing To Advance Universal Influenza Vaccine

Centivax, Inc., a clinical-stage biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets,...

 April 01, 2026 | News

Anumana Secures FDA Clearance For AI Algorithm Enabling Early Detection Of Pulmonary Hypertension

Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm...

 March 30, 2026 | News

Takeda Reports Strong Phase 3 Results For Zasocitinib In Plaque Psoriasis

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A signifi...

 March 30, 2026 | News

Eisai And Nuvation Bio Advance Taletrectinib With EMA Validation For ROS1 Positive Lung Cancer

 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company w...

 March 30, 2026 | News

Clarity Pharmaceuticals Signs Copper 64 Supply Agreement With Theragenics To Advance Radiopharmaceutical Commercialisation

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation pr...

 March 27, 2026 | News

Hope Medicine Initiates Phase III Trial Of HMI 115 For Endometriosis

Hope Medicine Inc., a science-driven, clinical-stage innovative biopharmaceutical company, announced that the first patient has been dosed in the Phase III...

 March 26, 2026 | News

Akeso Advances IO 2.0 Plus ADC 2.0 Strategy With Phase II Trial Clearance In China

Akeso, Inc. (9926.HK)  ("Akeso" or the "Company") announced  that it has received clearance from the Center for Drug Evaluation (CDE) of China's ...

 March 26, 2026 | News

BrightGene Reports Positive Phase 1 Results For Oral GLP 1 GIP Agonist BGM0504

BGM0504 shown to be generally well tolerated Overall safety, pk, and efficacy profile supports once-daily oral dosing BrightGene Bio-Medical Technology C...

 March 26, 2026 | News

Thermo Fisher Accelerates Clinical Intelligence Leadership With Strategic Clario Acquisition

Further strengthens Thermo Fisher’s position as the trusted partner to pharma and biotech customers, delivering important customer benefits Attracti...

 March 25, 2026 | News

Celosia Therapeutics Initiates Phase 1b Trial Of CTx1000 Targeting TDP 43 In ALS

CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS Celosia Therapeutics, an Australian biotech company developing advanced gen...

 March 25, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close